This explains the current guideline recommendations on using Apo B as the secondary target (after LDL-C) in hypertriglyceridemia, and it may be preferred over non-HDL-C in patients with high TG levels, DM, obesity, or very low LDL-C levels [6,18]. Here, APOB is linked to obesity due to melanocortin 4 receptor deficiency.